PUBLICATIONS BY STANISLAW RAJMUND BURZYNSKI AND ASSOCIATES
http://www.cancermed.com
2010
http://neuro-oncology.oxfordjournals.org/content/12/suppl_4/iv69.full.pdf?sid=252d3806-c450-4df0-8cf8-8ddf54d68db4
Burzynski, S.R, Weaver, R.A., Janicki, T.J., Burzynski, G.S., Szymkowski, B., Acelar, S.S.
OT-15
Preliminary results of a phase II study of antineoplastons A 10 and AS2-1 (ANP) in adult patients with recurrent mixed gliomas
Neuro-Oncology 2010;12(Suppl. 4):iv72
http://m.neuro-oncology.oxfordjournals.org/content/12/suppl_4/iv69.abstract
http://neuro-oncology.oxfordjournals.org/content/12/suppl_4/iv69.abstract
2010
Patil, S., Burzynski, S.R, Mrowczynski, E., Grela, K.
CB-15
Targeting microRNAs in glioma cells with antineoplastons
Neuro-Oncology 2010;12(Suppl. 4):iv10
http://neuro-oncology.oxfordjournals.org/content/12/suppl_4/iv7.abstract
2010
Burzynski, S.R, Weaver, R.A., Janicki, T., E. Szymkowski, B., Acelar, S.S., Burzynski, G.S.
A phase II study of antineoplaston A10 and AS2-1 injections in children with low i J r a d e astrocy1omas
Neuro-Oncology 2010 ; 12 (6):ii95
2010
Patil, S., Burzynski, S.R, Mrowczynski, E., Grela, K.
Antineoplastons initiate caspase induced apoptosis by suppressing survivin expression in U87 glioblastoma cells
Neuro-Oncology 2010;12(6):ii87
2009
Weaver, RA, Szymkowski, B., Burzynski, S.R
Over a 10-year survival and complete response ofa patient with diffuse intrinsic brainstem glioma (DBSG) treated with antineoplastons (ANP)
Neuro-Oncology 2009;11:923
2009
Burzynski, S.R., Janicki, T.J., Weaver, RA , Szymkowski, B., Burzynski, G.S.
Phase II study of antineoplastons A 10 and AS2-1 in patients with brainstem glioma:
Protocol BC-BT-11
Neuro-Oncology 2009;11:951
2009
Burzynski, S.R.
The coming pandemic of liver cancer:
In search of genomic solutions
In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume Xl;2009
http://www.lookfordiagnosis.com/videos.php?title=Coming+Pandemic+of+Liver+Cancer%3A+In+Search+of+Genomic+Solutions+-+Stanislaw+R.+…&content=Stanislaw+R.+Burzynski%2C+MD%2C+PhD+speaks+about+the+Coming+Pandemic+of+Liver+Cancer%3A+In+Search+of+Genomic+Solutions+at+16th+A4M+Conference+in+Las+…&lang=1
2009
Click to access Practical-application-of-gene-silencing-Volume-XI.pdf
Burzynski, S.R_
Practical application of gene silencing theory of aging
Life extension in animal testing and human clinical trials
In: American Academy ofAnti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume Xl ; 2009
2008
Patil, S., Burzynski, S., Chittur, S., Mrowczynski, E., Grela, K.
The ingredients of antineoplaston AS2-1 down-regulate glycolysis pathways in glioblastoma cells
Neuro-Oncology 2008;10:1148
2008
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2719003
Burzynski, S., Weaver, R., Janicki, T., Szymkowski, B., Burzynski, G.
Phase II study ofantineoplastons A10 and AS2-1 infusions (ANP) in patients with recurrent anaplastic astrocy1oma
Neuro-Oncology 2008;10:1067
2008
Patil, S., Burzynski, S., Chittur, S., Mrowczynski, E., Grela, K.
Antineoplaston AS2-1 affects cell cycle checkpoints, leading to apoptosis in human glioblastoma cells
Neuro-Oncology 2008;10:786
2008
http://europepmc.org/articles/PMC2666253
Burzynski, S., Weaver, R., Janicki, T., Burzynski, G., Samuel, S., Szymkowski, B.
Phase II study of antineoplastons A10 and AS2-1 (ANP) in patients with newly diagnosed anaplastic astrocy1oma:
A preliminary report
Neuro-Oncology 2008; 10:821
2008
Click to access PressRelease_05062009_BZYR.pdf
Burzynski, S.R., Weaver, R., Janicki, T., Walczak, M., Szymkowski, B., Samuel, S.
Phase II study of antineoplastons A 10 and AS2-1 (ANP) in children with optic pathway glioma:
A preliminary report
Neuro-Oncology 2008;10:450
2008
Burzynski, S.R.
The genes of life
Farmapress Publishers, 2008
2008
Click to access The-Genetic-Approach-to-Cancer-Treatment-2008.pdf
Burzynski, S.R.
Genomic approach to cancer treatment
In: American Academy ofAnti-Aging Medicine (A4M)
Anti-Aging Therapeutics, Volume X; 2008;37-44
2007
Click to access 42._Burzynski,_379-390.pdf
Burzynski, S.R.
Recent clinical trials in diffuse intrinsic brainstem glioma
Cancer Therapy 2007;5, 379-390
2007
http://europepmc.org/articles/PMC1994106
Burzynski, S.R., Weaver, R., Szymkowski, B.
A case report of a complete response and 20-year survival of a patient with a recurrent diffuse intrinsic brainstem anaplastic astrocytoma
Neuro-Oncology 2007;9:536
2007
http://europepmc.org/articles/PMC1994106
Patil, S., Burzynski, S.R., Mrowczynski, E., Grela, K.
Phenylacetylglutamine (PG) and phenylacetate (PN) interact additively to produce detachment-induced apoptosis/anoikis in glioblastoma cells
Neuro-Oncology 2007;9:482
2007
Click to access Publication_chapt%2010_AA%20Therapt%20Vol%20IX_2007.pdf
Burzynski, S.R.
The Genetic Solution forAnti-Aging
In: American Academy ofAnti-Aging Medicine (A4M) Anti· Aging Therapeutics, Volume IX; 2007;63-70
2007
Click to access Presentation_Chicago_July%202006.pdf
Burzynski, S.R.
Genetics of Brain Aging (1)
Gene Silencing in Neurons
In: American Academy ofAnti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume IX; 2007;71-78.
2007
Click to access Publication_chapt%2012_AA%20Therapt%20Vol%20IX_2007.pdf
Burzynski, S.R.
Genetics of Brain Aging (II)
Genetic Mechanisms in Encoding and Consolidation of Memory
In:
2007
Burzynski. S.R.• Weaver. RA. Janicki. T.J.•Jurida, G.F., Szymkowski. B.G.• Kubove. E.
Phase II studies of Antineoplastons A 10 and AS 2-1 (ANP) in children with newly diagnosed diffuse intrinsic brainstem gliomas
Neuro-Oncology 2007;9:206
Click to access pressrelease.pdf
2007
Burzynski. S.R.
The breakthrough in therapy and prevention in medicine of 21st century (5)
Genes and aging of the neurons
Geny a starzenie neuronow. Czasopismo Aptekarskie 2007; Nr 3 (159) 27-38
2007
Burzynski. S.R.
The breakthrough in therapy and prevention in medicine of 21st century (4)_
Time factor in biology and medicine
Czynnik czasu w biologii i medycynie. Czasopismo Aptekarskie 2007; Nr 2 (158) 27-36
2007
Burzy nski, S.R.
The breakthrough in therapy and prevention in medicine of 21st century (3)
The medicine of aging population
Medycyna starzejacego sie spoleczenstwa. Czasopismo Aptekarskie 2007; Nr 1 (157) 39-48
2006
https://www.novapublishers.com/catalog/product_info.php?products_id=5367
Burzynski, S.R.
Targeted Therapy for Brain Tumors
Columbus F, ed. Brain Cancer Therapy and Surgical Interventions. New York (NY); Nova Science Publishers, Inc. 2006;77-111
2006
Burzynski, S.R.
The breakthrough in therapy and prevention in medicine of 21st century (2)
Epigenome and gene silencing. Epigenom i wyciszanie genow. Czasopismo Aptekarskie 2006;Nr 12 (156) 29-36
2006
Burzynski, S.R.
The breakthrough in therapy and prevention in medicine of 21st century (1)
The medicine of genome an epigenome
Medycyna genomu i epigenomu. Czasopismo Aptekarskie 2006;Nr 11 (155) 45-52
2006
https://www.novapublishers.com/catalog/product_info.php?products_id=4028
Burzynski, S.R.
Age Management Treatments Which Target Silenced Genes
Redberry GW, ed. Gene Silencing: New Research. Nova Science Publishers, Inc. 2006
2006
Burzynski, S.R., Janicki, T.J., Weaver, RA, Szymkowski, B.G., Khan, M.L, Dolgopolov, V.
Treatment of multicentric brainstem gliomas with antineoplastons (ANP) A 10 and AS2-1
Neuro-Oncology. 2006;10:466
2006
Burzynski. S.R.•Weaver. RA. Szymkowski. B., Janicki. T.J.• Khan, M.L. Dolgopolov. V.
Complete response of a diffuse intrinsic brainstem tumor and von Hippel Lindau (VHL) disease to antineoplastons A 10 and AS2-1 (ANP):
a case report
Neuro-Oncology. 2006;10:439
2006
http://www.ncbi.nlm.nih.gov/m/pubmed/16774296
Burzynski. S.R.
Treatments for Astrocytic Tumors in Children:
Current and Emerging Strategies
Pediatric Drugs 2006;8:167-178
http://link.springer.com/article/10.2165%2F00148581-200608030-00003
2006
http://www.ncbi.nlm.nih.gov/m/pubmed/16484713
Burzynski. S.R., Janicki. T.J.•Weaver. RA, Burzynski, B.
Targeted therapy with AntineoplastonsA10 and AS2-1 of high grade, recurrent. and progressive brainstem glioma
Integrative Cancer Therapies 2006; 5(1):40-47
http://ict.sagepub.com/content/5/1/40.abstract
Integr Cancer Ther. 2006 Mar;5(1):40-7
http://m.ict.sagepub.com/content/5/1/40.short
2006
Burzynski, S.R., Weaver, RA, Janicki, T.J., Szymkowski, B.G., Jurida, G.F., Burzynski, B.
Phase II studies of antineoplastons A 10 and AS2-1 (ANP) in patients with recurrent, diffuse intrinsic brain stem gliomas
Neuro-Oncology 2006;10:346_
2006
Click to access Publication_Master%20Clock%20II_AA%20Therapt%20Vol%20VIII_2006.pdf
Burzynski, S.R.
Master Clock of Life (II)
How to Turn the Clock Back
In: American Academy ofAnti-Aging Medicine. American Academy ofAnti-Aging Medicine (A4M) Anti-Aging Therapeutics;Volume VIII 2006
2006
Burzynski, S.R.
Master Clock of Life (1)
“Junk DNA.” and Promoters Regions as Major Components ofthe Clock
American Academy ofAnti-Aging Medicine (A4M) Anti-Aging Therapeutics;Volume VIII 2006
2005
Click to access Publication_Master%20Clock%20II_AA%20Therapt%20Vol%20VIII_2006.pdf
Burzynski, S. R.
Gene silencing theory of aging:
the clinical trial supporting the theory
Anti-Aging Therapeutics 2005;Vol Vll:39-46
http://www.a4m.com/assets/pdf/bookstore/aamt_vol7_toc.pdf?SESSION_MAIN=rhu6d1mfnjhkon8865nciot5v2
2005
Burzynski, S.R.,Weaver, RA,Janicki,T.J., Burzynski, B.,Jurida, G.
TargetedtherapywithANP inchildren less than 4 years old with inoperable brain stem gliomas
Neuro-Oncology 2005;7:300
2005
Weaver, RA , Burzynski, S.R., Janicki, T.J., Burzynski, B., Jurida, G., Szymkowski, B.
Long-term survival in patients with glioblastoma multiforme treated in phase II studies with ANP
Neuro-Oncology 2005;7:299
2005
http://ict.sagepub.com/content/4/2/168.abstract
Burzynski, S.R., Weaver. RA, Janicki, T.• Szymkowski, B., Jurida, G.• Khan, M.• Dolgopolov, V.
Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with Antineop!astons A 10 AS2-1
Integrative CancerTherapies 2005;4(2):168-177
2005
http://www.ncbi.nlm.nih.gov/m/pubmed/15533642
Burzynski. S.R.
Aging: Gene silencing or gene activation?
Med Hypoth 2005; 64, 201-208
http://www.medical-hypotheses.com/article/S0306-9877(04)00376-7/abstract
Med Hypotheses. 2005;64(1):201-8
http://www.medical-hypotheses.com/article/S0306-9877(04)00376-7/references
http://www.sciencedirect.com/science/article/pii/S0306987704003767
http://www.journals.elsevierhealth.com/periodicals/ymehy/article/PIIS0306987704003767/abstract
http://www.journals.elsevierhealth.com/periodicals/ymehy/article/S0306-9877(04)00376-7/abstract
PDF:
Click to access Publication_Gene%20Silencing%20or%20Gene%20Activation_Med%20Hypoth%202005.pdf
References:
http://www.medical-hypotheses.com/article/S0306-9877(04)00376-7/references
2004
Burzynski. S.R.
Mechanizmy i profilaktyka genetycznego starzenia. Mechanisms and prevention of genetic aging
Neurologia I Psychiatria 2004;4:1-8
2004
Burzynski, S.R., llkowska-Musial, E., Klimczak M.W., Musial. L
Antineoplastons In Dairy Products
Journal of
Applied Nutrition 2004;54;1-8
2004
Burzynski, S.R., Weaver, R. Sestak. M., Lewy, R.L, Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V.
Long-term survivals in phase II studies ofAntineoplastons A10 and AS2-1 (ANP) in patients with diffuse intrinsic brain stem glioma
Neuro-Oncology 2004;6:386
2004
Weaver, RA, Burzynski, S.R., Sestak, M., Lewy, R.L, Janicki, T.J., Szymkowski, B., Jurida, G., Khan, M.L, Dolgopolov, V.
Phase II study ofAntineoplastons A10 and AS2-1 (ANP) in recurrent glioblastoma multiforme
Neuro-Oncology 2004;6:384
2004
Burzynski, S.R., Weaver, R. Sestak. M., Janicki, T., Szymkowski, B., Jurida, G., Khan, M., Dolgopolov, V.
Treatment of primitive neuroectodermal tumors (PNET) with antineoplastons A 10 and AS2-1 (ANP)
Preliminary results of phase II studies
Neuro-Oncology 2004;6:428
2004
Burzynski, S.R., Weaver, R. Sestak. M., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V.
Phase II studies of antineoplastons A 10 and AS2-1 (ANP) in children with atypical teratoid/rhabcoid tumors (AT/RT) ofthe central nervous system. A preliminary report. Neuro-Oncology 2004;6:427
2004
http://www.ncbi.nlm.nih.gov/m/pubmed/15312271
Burzynski, S.R., Lewy, R.L, Weaver, R., Janicki, T., Jurida, G., Khan, M., Larisma, C.B., Paszkowiak, J., Szymkowski, B.
Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme
Integrative Cancer Therapies 2004;3:257-261
http://ict.sagepub.com/content/3/3/257.abstract
Integr Cancer Ther. 2004 Sep;3(3):257-61
http://m.ict.sagepub.com/content/3/3/257.short
2004
http://www.ncbi.nlm.nih.gov/m/pubmed/15563234
Burzynski, S.R., Weaver, R., Lewy, R., Janicki, T. Jurida, G., Szymkowski, B., Khan, M., Sestak, M.
Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma
A Preliminary Report
Drugs R&D 2004;5(6):315-326
http://www.ingentaconnect.com/content/adis/rdd/2004/00000005/00000006/art00002
Drugs R D. 2004;5(6):315-26
2004
http://www.ncbi.nlm.nih.gov/m/pubmed/15035876
Burzynski, S.R.
The Present State ofAntineoplaston Research
Integrative Cancer Therapies 2004;3:47-58
http://ict.sagepub.com/content/3/1/47.abstract
Integr Cancer Ther. 2004 Mar;3(1):47-58
http://ict.sagepub.com/content/3/1/47.short
2003
http://www.ncbi.nlm.nih.gov/m/pubmed/12718563
Burzynski. S.R.• Lewy, R.L, Weaver. RA. Alder. M.L. Janicki. T.J.•Jurida, G.F., Paszkowiak. JK, Szymkowski. B.G.• Khan. M.L, Sestak, M.
Phase II Study ofAntineoplastons A10 and AS2-1 in Patients with
Phase II study of antineoplaston
A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report
http://www.ingentaconnect.com/content/adis/rdd/2003/00000004/00000002/art00002
Drugs R D. 2003;4(2):91-101
2003
W aldbillig R. Burzynski SR. Mechanism of action. uptake. and gene array studies on the antineoplastic agent phenylacetylglutamine (PG) in human glioma cells U-87
Neuro-Oncology 2003;10:309
2003
Burzynski. S.R.• W eaver. R A . Sestak. M.• Lewy, R.I.. Janicki. T.J.• Jurida. G.F.• Paszkowiak. J.K.. Szymkowski. B.G.• Khan. M.l.
Phase II study ofAntineoplastons A10 and AS2-1 (ANP) in children with recurrent and progressive multicentric glioma
A preliminary report
Neuro-Oncology 2003;10:3S8
2003
http://www.scribd.com/mobile/doc/26344902
Burzynski. S.R.
The Methylation Control of Gene Activation and Silencing Theory
The Basic Principles and Practice ofAnti-Aging Medicine & Age Management for the Aesthetic Surgeon and Physician
Vincent C. Giampapa (Ed.) 2003;33-4
2003
Burzynski, S.R., Maxwell L. Axler, Robert I. Lewy, Tomasz Janicki, Elwira llkowska-Musial. Anna Baranowska. M.Sc.
Amino Acid Supplementation in Treatment of Cancer-Related Symptoms
Journal ofApplied Nutrition 2003; S3:S2-60
2003
http://www.ncbi.nlm.nih.gov/m/pubmed/12615527
Burzynski, S. R.
Gene Silencing – A New Theory ofAging
Med Hypoth 2003; 60:S78-S83
http://www.medical-hypotheses.com/article/S0306-9877(03)00050-1/abstract
Med Hypotheses. 2003 Apr;60(4):578-83
References:
http://www.medical-hypotheses.com/article/S0306-9877(03)00050-1/references
2002
Burzynski, S.R.
Antineoplaston Therapy
Chapter in Integrative Oncology – Conventional and Complementary
Strategies
Urban & Fischer; 2002
2000
Burzynski, S.R.
Antineoplastons
In: Clinician’s Complete Reference To Complementary/Alternative Medicine,
Novey, D. W. (Ed.). Mosby 2000;496-S07, St.Louis, USA
2000
Burzynski, S.R.
The Best ofAlternative Medicine
Townsend Letter for Doctors 2000;200:32
1999
http://www.ingentaconnect.com/content/adis/cdi/1999/00000018/00000001/art00001?crawler=true
Burzynski, S.R., Conde, A.B.• Peters, A., Saling B., Ellithorpe, R., Daugherty , J.P., and Nacht C.H.
A Retrospective Study ofAntineoplastons A10 and AS2-1 in Primary Brain Tumors
Clin. Drug Invest 1999;18:1-10
1999
http://www.ncbi.nlm.nih.gov/m/pubmed/10377942
Burzynski. S.R.
Efficacy of Antineoplastons A 10 and AS2-1
Mayo Clin. Proc 1999;74:641-643
http://www.sciencedirect.com/science/article/pii/S0025619611641438
References:
http://www.mayoclinicproceedings.org/article/S0025-6196(11)64143-8/references
1998
Burzynski. S.R.
Antineoplastons in the treatment of malignant brain tumors
Anti-Aging Medical Terapeutics. vol.
2. Klatz RM.• Goldman R. (Ed)
Health Quest Publications 1998;28-34. Marina del Rey, Ca. USA
1997
Burzynski. S.R.
Antineoplastons. oncogenes and cancer
Anti-Aging Medical Therapeutics, Vol.1. Klatz RM.
Goldman R. (Ed)
Health Quest Publication 1997; Marina del Rey, CA. USA
1995
http://www.ncbi.nlm.nih.gov/m/pubmed/8535046
Burzynski, S.R.
Potential of antineoplastons in diseases of old age
Drugs & Aging 199S;7:1S7-167
http://link.springer.com/article/10.2165/00002512-199507030-00001?no-access=true
Drugs Aging. 1995 Sep;7(3):157-67
1995
Soltysiak-Pawluczuk, D., Burzynski, S.R., Feldo, M., Majewska, B., Kleinrok, Z.
Cellular accumulation of antineoplaston AS2-1 in human hepatoma cells
Cancer Letters 88 (1995);88:107-112
1995
http://www.ncbi.nlm.nih.gov/m/pubmed/8529528
Juszkiewicz, M., Chodkowska, A., Burzynski, S.R., Mlynarczyk, M., Kleinrok, Z.
The influence of antineoplaston AS on particular subtypes of central dopaminergic receptors
Drugs Exptl Clin Res 199S;21:1S3-1S6
http://journals.indexcopernicus.com/abstracted.php?icid=615614
Drugs Exp Clin Res. 1995;21(4):153-6
1994
http://www.ncbi.nlm.nih.gov/m/pubmed/7813388
Juszkiewicz, M., Chodkowska, A., Burzynski, S.R., Feldo, M., Majewska, B., Kleinrok, Z.
The influence of antineoplaston AS on the central dopaminergic structures
Drugs Exptl Clin Res 1994;20:161-167
http://journals.indexcopernicus.com/abstracted.php?icid=615613
Drugs Exp Clin Res. 1994;20(4):161-7
1993
Burzynski, S.R.
lmmunosurveillance versus chemosurveillance
Post Nauk Med 1993;6:260-262
1993
Burzynski. S.R.
Antineoplastons
An Investigational CancerTherapy
Townsend Letter for Doctors 1993;3,1S0-1S3
1992
Burzynski. S.R.
Novel differentiation inducers
Recent Advances in Chemotherapy
Adam D. (Ed). Futuramed
Publishers. 1992; Munich. Germany
1992
Liau. M.C.• Liau. C.P.• Burzynski. S.R.
Potentiation of induced terminal differentiation by phenylacetic acid and related chemicals
lnternat J Exptl Clin Chemother 1992;S:9-17
1992
Liau, M.C., Luong, Y., Liau, C.P., Burzynski, S.R.
Prevention of drug induced DNA hypermethylation by antineoplaston components
Internal J Exptl Clin Chemother 1992;S:19-27
1992
Lee, S.S., Bu rzynski, S.R.
Synergistic Effect of Antineoplaston A S and Retinoic Acid on the Induction of Human Promyelocytic Leukemia line HL-60
Recent Advances in Chemotherapy
Adam D. (Ed), Futuramed Publishers. 1992: Munich, Germany
1992
Liau, M.C., Luong, Y., Liau, C.P., Burzynski, S.R.
Prevention of drug-induced DNA hypermethylation by antineoplastons
Recent Advances in Chemotherapy
Adam D. (Ed), Futuramed Publishers. 1992; Munich, Germany
1992
Burzynski , S.R , Kubove , E., Burzynski, B.
Phase II clinical trials of antineoplastons A10 and AS 2- 1 infusions in astrocytoma
Recent Advances in Chemotherapy
Adam D. (Ed), Futuramed Publishers. 1992; Munich, Germany
1991
Lee, S.S., Burzynski, S.R. Antineoplaston AS:
A growth inhibitor for cancerous cells and growth stimulator for normal cells
Internal J Exptl Clin Chemother 1991;4:63-6S
1990
Kampalath, B.N., Liau, M.C., Burzynski, B., Burzynski, S.R.
Protective effect ofantineoplaston A10 in hepatocarcinogenesis induced by aflatoxin 81
Internal J Tissue Reactions 1990;12 (supp1):43-SO
1990
Liau, M.C., Lee, S.S., Burzynski, S.R
Modulation of cancer methylation complex isoenzymes as a decisive factor in the induction of terminal differentiation mediated by antineoplaston A5
Internat J Tissue Reactions 1990; 12 (suppl): 27-36
1990
Lee, S.S.• Burzynski. S.R.
Inducibility of HL-60 leukemic cells to undergo terminal differentiation after repeated treatment with antineoplaston A5
Internat J Exptl Clin Chemother 1990;3:12S-128
1990
Lee, S.S.• Burzynski. S.R.
Induction ofdifferentiation of HL-60 human promyelocytic leukemic cell by antineoplaston A5
Internal J Tissue Reactions 1990;12(suppl):37-42
1990
Liau, M.C.• Ashraf. A.a.. Lee. S.S.• Hendry, L.B., Burzynski. S.R.
Riboflavin as a minor active anticancer component of antineoplaston A2 and A5
Internal J Tissue Reactions 1990;12:19-26
1990
Liau, M.C., Lee, S.S., Burzynski, S.R.
Separation of active anticancer components of antineoplaston A2, A3, and A5
Internat J Tissue Reactions 1990; 12 (suppl): 1-17
1990
http://www.ncbi.nlm.nih.gov/m/pubmed/2152694
Burzynski, S.R., Kubove, E., Burzynski, B
Treatment of hormonally refractory cancer ofthe prostate with antineoplaston AS2-1
Drugs Exptl Clin Res 1990;16: 361-369
Drugs Exp Clin Res. 1990;16(7):361-9
Burzynski, S.R.
Isolation, purification and synthesis of antineoplastons
Internal J Exptl Clin Chemother
l~tl~;;!:b:J-b~-
l~tl~;;!:b:J-b~
1989
Liau, M.C., Lee, S.S., Burzynski, S.R
Hypomethylation of nucleic acids:
A key to the induction of terminal
differentiation
Internal J Exptl Clin Chemother 1989;2:187-199
1988
Hendry, LB., Muldoon, T.G., Burzynski, S.R
Modeling studies suggest the modified dipeptide analog
phenylacetylamino-2, 6-piperidinedione may interact with DNA
Adv Exptl Clin Chemother. 1988; 2: 11-13.
1988
Burzynski, S.R
Antineoplastons:
Basic research and clinical applications
Adv Exptl Clin Chemother_1988; 2:
1-9_
1988
Burzynski, S.R
Isolation, purification and synthesis of antineoplastons
Adv Exptl Clin Chemother_1988; 6: 1-7_
1988
Liau, M.C., Lee, S.S, Burzynski, S.R
Differentiation inducing components of antineoplaston A5
Adv Exptl Clin Chemother. 1988; 6: 9-2S
1988
Lee, S.S ., Burzy nski, S R
Terminal differentiation of HL-60 human promyelocytic leukemia cells induced by antineoplaston A2
Adv Exptl Clin Chemother 1988;6:27-31
1988
Burzynski, S.R.
Treatment of bladdercancer with antineoplaston formulations
Adv Exptl Clin Chemother. 1988. 2: 37-46
1988
Burzynski, S.R., Kubove, E ., Burzynski, B.
Phase I clinical studies of oral formulation of antineoplaston AS2-1
Adv Exptl Clin Chemother 1988;2:29-36
1988
Burzynski, S.R.
Treatment of malignant brain tumors with antineoplastons
Adv Exptl Clin Chemother 1988;6:45- 56
1988
Ashraf, AQ., Kampalath, B.N., Burzynski, S.R
Pharmacokinetic analysis of antineoplaston A10 injections following intravenous administration in rats
Adv Exptl Clin Chemother 1988;6:33-39
1988
Ashraf, AQ.,Burzynski, S.R.
Comparative study of antineoplaston A10 levels in plasma of healthy people and cancer patients
Adv Exptl Clin Chemother 1988;2 : 19-28
1987
Lee, S.S., Burzynski, S.R
Tissue culture and animal toxicity studies of antineoplaston AS
Drugs Exptl Clin Res 1987;13 (suppl 1):31-3S_
1987
Kampalath, B.N., Liau, M.C., Burzynski, B., Burzynski, S.R.
Chemoprevention by antineoplastonA10 ofbenzo (a) pyrene-induced pulmonary neoplasia
Drugs Exptl Clin Res 1987;13 (suppl 1):S1-SS_
1987
Liau, M.C., Szopa, M., Burzynski, B., Burzynski, S.R
Chemoswveillance:
A novel concept of the natural defense mechanism against cancer
Drugs Exptl Cline Res 1987;13 (suppl 1):71-76
1987
Lee, S.S., Mohabbat, M.O., Burzynski, SR
In vitro cancergrowth inhibition and animal toxicity studies of antineoplaston A3
Drugs Exptl Clin Res 1987;13 (suppl1):13-16
1987
Khalid, M., Burzynski, S.R.
N,N’-<Jisubstituted L-isoglutamines as novel cancer chemotherapeutic agents
Drugs Exptl Clin Res 1987;13 (suppl 1):S7-60
1987
Hendry, LB., Muldoon, T.G., Burzynski, S.R., Copland, JA, Lehner, A.F.
Stereochemical modeling studies of the interaction of antineoplaston A 10 with DNA
Drugs Exptl Clin Res 1987;13 (suppl 1):77-81
1987
Burzynski, S.R., Kubove, E .
Initial clinical study with antineoplaston A2 injections in cancer patients with five years follow-up
Drugs Exptl Clin Res 1987;13 (suppl1):1-12
1987
Burzy nski, S.R., Kubove, E .
Phase I clinical studies of antineoplaston A3 inJections_
Drugs Exptl Clin Res 1987;13 (suppl 1):17-29
1987
Burzynski, S.R., Kubove, E., Burzynski, B.
Phase I clinical studies of antineoplaston AS injections_
Drugs ExptL Clin Res 1987;13 (suppl 1):37-43
1987
Liau, M.C., Szopa, M., Burzynski, B., Burzynski, S.R_
Quantitative assay of plasma and urinary peptides as an aid for the evaluation ofcancer patients undergoing antineoplaston therapy.
Drugs Exptl Clin Res 1987;13 (suppl 1) :6 1-7 0
1987
Ashraf, A Q., Liau, M.C., Kampalath, B.N., Burzynski, S.R
Pharmacokinetic study of radioactive antineoplaston A10followingoraladministrationinrats_
DrugsExptlClinRes 1987;13(suppi1):4S-SO_
1986
Burzynski, S.R., Mohabbat M_Q_
Chronic animal toxicity studies of antineoplaston A2.
Drugs Exptl Clin Res 1986;12 (suppl 1):73-7S_
1986
Ashraf, AQ., Liau, M.C., Mohabbat, M.O., Burzynski, S.R_
Preclinical studies ofantineoplastonA10 injections_
Drugs Exptl Clin Res 1986;12 (suppl 1):37-4S_
1986
Burzynski, S. R. , Mohabbat, M. O. , Le e, s _s _ Pre clinical studies of antineoplaston AS2-1 and antineoplaston AS2-S
Drugs Exptl Clin Res 1986;12 (suppl1):11-16
1986
Burzynski, S.R.
Antineoplaston A3
Drugs ofthe Future 1986;11:SS1-SS2
1986
Burzynski, S.R.
Antineoplastons – History ofthe research (1)
Drugs Exptl Clin Res 1986;12 (suppl1):1-9
1986
Burzynski, S.R.
Antineoplaston AS2-5
Annual Drug Data Report 1986;8:319
1986
Burzynski, S.R.
Antineoplaston AS2-1
Annual Drug Data Report 1986;8:320
1986
Burzynski, S.R., Khalid, M_
Antineoplaston AS2-S
Drugs of the Future 1986;11:364-36S_
1986
Burzynski, S.R_
AntineoplastonA10injections_
Annual Drug Data Report 1986;8:S97_
1986
Burzynski, S.R_
Antineoplaston A3
Annual Drug Data Report 1986;8:4 12
1986
Burzynski, S.R.
Antineoplaston A2
Annual Drug Data Report 1986;8:S04
1986
Burzynski, S.R., Khalid, M.
Antineoplaston AS2-1
Drugs of the Future 1986; 11: 361-363
1986
Burzynski, S.R.
Antineoplaston A2
Drugs ofthe Future 1986;11:549-550
1986
Burzynski, S.R.
Antineoplaston AS
Annual Drug Data Report 1986;8:869
1986
Burzynski, S.R_
Antineoplaston AS
Drugs ofthe Future 1986;11:824-82S
1986
Burzynski, S.R_
Synthetic antineoplastons and analogs
Drugs ofthe Future 1986;11: 679-688
1986
Liau, M.C., Burzynski, S R
Altered methylation complex isoenzymes as selective targets for cancer chemotherapy
Druos Exotl Clin Res 1986:12 (suool 1\:77-86.
1986
Lehner, A.F., Burzynski, S.R., Hendry, L.B.
3-phenylacetylamino-2, 6-piperidinedione, a naturally occurring peptide analog with apparent antineoplastic activity may bind to DNA.
Drugs Exptl Clin Res 1986;12 (suppl 1):57-72
1986
Burzynski, S.R., Kubove, E.
Toxicology studies ofantineoplastonA10injections incancer patients
Drugs Exptl Clin Res 1986;12 (suppl 1):47-55
1986
Burzynski, S.R.
Toxicology studies of antineoplaston AS2-5 injections in cancer patients
Drugs Exptl Clin Res 1986;12 (suppl 1):17-24
1986
Burzynski, S.R., Burzynski, B., Mohabbat, M.O.
Toxicology studies of antineoplaston AS2-1 injections in cancer patients
Drugs Exptl Clin Res 1986;12 (suppl 1):25-35
1986
Burzynski, S., Mohabbar. M., Lee, S.
Preclinical studies of antineoplaston AS2-1 in mice with oral administration
Drugs Exptl Clin Res 1986;132
1985
Lee, S.S., Mohabbat, M.O., Burzynski, S.R.
Tissue culture and acute animal toxicity studies of antineoplaston A2
Future Trends in Chemotherapy 1985;6:481-484
1985
Burzynski, S.R., Hai TI.
Antineoplaston A10
Drugs of the Future 1985;10:103-105
1985
Burzynski, S.R.
Phase I clinical studies of antineoplaston AS2-5 injections
Recent Advances in Chemotherapy
lshigami J. (Ed). University ofTokyo Press. 1985; Tokyo, Japan
1985
Burzynski, S.R.• Mohabbat. M.O., Burzynski, B.
Toxicology studies on oral formulation of antineoplaston A 10 in cancer patients
Future Trends in Chemotherapy 1985;6:485-493
1984
Burzynski, S.R., Mohabbat MO, Burzynski B.
Animal toxicology studies on oral formulation of antineoplaston A10
Drugs Exptl Clin Res 1984;10:113-118
1984
Lee, S.S., Mohabbat, M.O., Burzynski, S.R.
Tissue culture and animal toxicity studies of antineoplaston A2
Drugs Exptl Clin Res 1984;10:607-610
1984
Burzynski,S.R.
Antineoplaston A10
AnnualDrugDataReport 1984;6:124
1984
Burzynski, S.R., Mohabbat, M.O., Burzynski, B.
Human toxicology studies on oral formulation of antineoplaston A10
Drugs Exptl Clin Res 1984;10:891-909
1984
Burzynski,S.R.,Mohabbat,M.O.,Burzynski,B.
Toxicology studiesonoralformulationofantineoplastonA10 in cancer patients
Drugs Exptl Clin Res 1984;10:611-619
1979
Beall, P., Szopa, B., Burzynski, S.R., Hazlewood, C.F.
Polypeptides that inhibit human breast cancer cell division
Cancer Biochem Biophys 1979;3:93-96
1978
Burzynski, S.R.
Antyneoplastony
Przeglad Lekarski 1978;6:583-586
1977
Gross S, Galicka N. Grabarczyk M. Giannini M. Burzynski SR. Stolzmann Z.
Urinary peptides inhibit DNA
synthesis in vitro in certain cultured neoplastic cells
Clin Chern 1977;23:148-149
1977
Burzynski, S.R., Stolzmann. Z., Szopa, B., Stolzmann. E., Kaltenberg, O.P.
Antineoplaston A in cancer therapy
(1)
Physiol Chern Phys 1977;9:485-500
1976
Burzynski, S.R.
Antineoplastons:
Biochemical defense against cancer
Physiol Chern Phys 1976;8:275-279
1976
Gross, S., Galicka, N., Burzynski, S.R., Stolzmann, A.
Urinary peptides in muscular dystrophy
Physiol Chern Phys 1976;8:161-166
1976
Burzynski, S.R
Sequential analysis in subnanomolar amounts of peptides; Determination of the structure of a habituation-induced brain peptide (ameletin)
Anal Biochem 1976;70:359-365
1976
Burzynski, S.R., Lao, T.L., Ho, D.H., Rao, P.N., Georgiades, J., Kratzenstein, H.
Biologically active peptides in human urine:
Ill. Inhibitors ofthe growth of leukemia, osteosarcoma and HeLa cells
Physiol Chern Phys 1976;8: 13-22
1976
Burzynski, S.R., Rao, P.N., Gross, S., Stolzman, Z.
lnhibition of the Growth ofHeLa Cells bythe Peptide Isolated from Normal Human Urine
Fed Proc 1976;35:623
1975
Burzynski. S.R.
Quantitative analysis of amino acids and peptides in the femtomolar range
Anal Biochem 1975;65:93-99
1975
Burzynski. S.R.. Ungar. G.
Brain Peptides Associated with Habituation to a Sound Stimulus
Neuroscience Abstracts 1975;1:329
1975
Ungar. G., Burzynski, S.R.• Tate. D.L.
Learning-induced Brain Peptides
Peptides:
Chemistry, structure and biology
Walter. R., Meienhofer. J. (Ed). Ann Arbor Science; 1975; Ann Arbor. Michigan. USA
1974
Burzynski, S.R., Ungar, A.L., Lubanski, E.
Biologically active peptides in human urine:
II. Effect on intestinal smooth muscle and heart
Physiol Chern Phys 1974;6:457-468
1974
Burzynski, S.R., Ungar, A.L., Lubanski, E.
Effect of Urinary Peptides on Smooth Muscle and Heart
Fed Proc 1974;33:547
1973
Burzynski, S.R.
Biologically active peptides in human urine:
L Isolation of a group of medium-sized peptides
Phy siol Chern Phy s 1973;5:437-447
1973 – Biologically active peptides in human urine
I. Isolation of a group of medium-sized peptides
http://www.ncbi.nlm.nih.gov/m/pubmed/4775589
S R Burzynski
Physiol Chem Phys 5(5):437-47 (1973), PMID .4775589
Cited by:
5/1992 – 4) – Japan – Tsuda
Jpn. J. Cancer Res. 83, 527-531
1988 – – A10 – Hendry & Muldoon – J rSteroid Biochem. 1988;30(1-6):325-8
1973
Burzynski, S.R., Georgiades, J.
Effect of Urinary Peptides on DNA, RNA and Protein Synthesis in Normal and Neoplastic Cells
Fed Proc 1973;32:766
1973
Ungar, G., Burzynski, S.R
Isolation and Purification of a Habituation-inducing Peptide from Trained Rat Brain
Fed Proc 1973;32:367
1970
Burzynski , S., Czerniak, Z.
A simple method for the separation of free and bound amino acids and its application to the identification of bound amino acids in human blood serum
Chern Anal 1970;15:223-225
__________________________
1970 – Burzyński S
http://www.ncbi.nlm.nih.gov/m/pubmed/5531748
[Free amino acids in serum of obese children]
Endokrynol Pol. 1970;21(6):611-7. Article in Polish
1970
Szajner-Milart, J., Burzynski. S.R . Paczos-Chadyma. E.. Czerniak, Z.
Free amino acids in serum of obese children
Endokr Pol 1970;21:611-617
1969
Krzeczkowska, 1., Czerniak, Z.. Burzynski. S.
Quantitative determinations of carbohydrates and their statistical analysis
L Results obtained in various conditions using paper and thin-layer chromatography
Chern Anal
1969; 1 3 : 1221-1228
1969
Burzynski. S.
Investigations on unknown ninhydrin-reacting substances in human blood serum L Attempts at identification ofthree such substances
Experientia 1969;25:490-491
1969
http://www.ncbi.nlm.nih.gov/m/pubmed/5801388
Burzynski. S.
Bound amino acids in serum of patients with chronic renal insufficiency
Clin Chim Acta 1969;25:231 -237
http://www.sciencedirect.com/science/article/pii/0009898169902599
Clin Chim Acta. 1969 Aug;25(2):231-7
Clinica Chimica Acta
Volume 25, Issue 2, August 1969, Pages 231–237
__________________________
8/1969 – Burzyński S
http://www.ncbi.nlm.nih.gov/pubmed/5801388
Clin Chim Acta. 1969 Aug;25(2):231-7
1969
http://www.ncbi.nlm.nih.gov/m/pubmed/5797414
Czerniak, Z., Burzynski, S.
Free amino acids in serum of patients with chronic renal insufficiency
Clin Chim Acta 1969;24:367-372
http://www.sciencedirect.com/science/article/pii/0009898169901077
Clin Chim Acta. 1969 Jun;24(3):367-72
Clinica Chimica Acta
Volume 24, Issue 3, June 1969, Pages 367–372
__________________________
6/1969 – BURZYNSKI S
http://www.ncbi.nlm.nih.gov/pubmed/5797414
Clin Chim Acta. 1969 Jun;24(3):367-72
__________________________
5/1969 – BURZYNSKI S
http://www.ncbi.nlm.nih.gov/m/pubmed/5796158
Investigations on unknown ninhydrin-reacting substances in human blood serum
I. Attempts at identification of 3 such substances
Experientia. 1969 May 15;25(5):490-1
1969
Burzynski, S., Czerniak, Z.
A simple method for free and bound amino acid separation
Folia Soc Sci Lub 1969/70;Sec. A-D 9/10 (suppl):143-144
1969
Burzynski, S., Czerniak, Z.
Quantitative determination of amino acids using photometry of negative printed chromatograms
Modification of the method and its application for amino acid analysis in blood serum
Chern Anal 1969;14:667-671
1969
Czerniak, Z., Burzynski, S.
Qualitative analysis of amino acids using the multiple development of chromatograms in different eluents
Chem Anal 1969;14:673-676
1968
Krzeczkowska, L, Czerniak, Z., Burzynski, S.
Quantitative determinations of free amino acids in the blood of patients with myocardial infarction using a new method of photometry of the negative printed chromatograms
Pol Arch Med Wewn 1968;41:361-368
1968
Krzeczkowska, L, Czerniak, Z., Burzynski, S.
Quantitative determinations of free amino acids in human blood with the use of our own method and Beckman amino acid analyzer
Pol Arch Med W ewn 1968;40:223-228
__________________________
1968 – BURZYNSKI S
http://www.ncbi.nlm.nih.gov/m/pubmed/5669683
[Quantitative determination of amino acids in human blood with the use of our method and Beckman’s “amino acid analyser”]
Pol Arch Med Wewn. 1968;40(2):223-8. Article in Polish
1968
Krzeczkowska, L, Czerniak, Z.. Burzynski, S.
Quantitative determinations of carbohydrates and their statistical analysis, IL Analysis of variance for four-crossed classification and Tukey confidence intervals
Chern Anal 1968; 13: 1229-1238
1968
Burzynski. S.
Investigations on amino acids and peptides in blood serum of healthy people and patients with chronic renal insufficiency
1968; Lublin. Poland: 274 pp (doctoral dissertation)
__________________________
1966 – BURZYNSKI S
http://www.ncbi.nlm.nih.gov/m/pubmed/5996263
[The application of the photometry of negative printed chromatograms for quantitative determination of free amino acids in the blood of healthy people]
Ann Univ Mariae Curie Sklodowska Med. 1966;21:313-22. Article in Polish
1966
Krzeczkowska. 1., Czerniak. Z., Burzynski, S.
The application ofthe negative printed chromatograms for quantitative determination of free amino acids in the blood of healthy people
Ann Univ MC Sklodowska 1966; 2 1: 313-322
1966
http://www.ncbi.nlm.nih.gov/m/pubmed/5996246
Krzeczkowska. 1., Burzynski, S. Czerniak Z.
Quantitative determination of amino acids using photometry of negative printed chromatograms
Ann Univ MC Sklodowska 1966;21:125-134
Ann Univ Mariae Curie Sklodowska Med. 1966;21:125-34. Article in Polish
1965
Krzeczkowska, 1., Burzynski, S., Czerniak. Z.
Investigations on the possibility ofthe determination of mushroom species on the basis ofthe composition of their amino acids
Ann Univ MC Sklodowska 1965;20:221-229
1965
Krzeczkowska, L, Czerniak, Z., Burzynski, S.
Free and bound amino acids of some edible mushrooms
Ann Univ MC Sklodowska 1965;20:303-312
1964
http://www.ncbi.nlm.nih.gov/m/pubmed/5893108
Krzeczkowska, L, Czerniak, Z., Burzynski, S.
Bound amino acids of some edible mushrooms
Ann Univ MC Sklodowska 1964;19:329-336
Ann Univ Mariae Curie Sklodowska Med. 1964;19:329-36. Article in Polish
1964
http://www.ncbi.nlm.nih.gov/m/pubmed/5893107
Krzeczkowska, L, Burzynski, S., Czerniak, Z.
Free amino acids of some edible mushrooms
Ann Univ MC Sklodowska 1964;19:321-328
Ann Univ Mariae Curie Sklodowska Med. 1964;19:321-8. Article in Polish
1986
Lehner, A.F., Burzynski, S.R., Hendry, L.B.
3-phenylacetylamino-2, 6-piperidinedione, a naturally occurring peptide analog with apparent antineoplastic activity may bind to DNA
Drugs Exptl Clin Res 1986;12 (suppl 1):57-72
1986
Burzynski, S.R., Kubove, E.
Toxicology studies ofantineoplastonA10injections incancerpatients
Drugs Exptl Clin Res 1986;12 (suppl 1):47-55
1986
Burzynski, S.R.
Toxicology studies of antineoplaston AS2-5 injections in cancer patients
Drugs Exptl Clin Res 1986;12 (suppl 1):17-24
1986
Burzynski, S.R., Burzynski, B., Mohabbat, M.O.
Toxicology studies of antineoplaston AS2-1 injections in cancer patients
Drugs Exptl Clin Res 1986;12 (suppl 1):25-35
1986
Burzynski, S., Mohabbar. M., Lee, S.
Preclinical studies of antineoplaston AS2-1 in mice with oral administration
Drugs Exptl Clin Res 1986;132
1985
Lee, S.S., Mohabbat, M.O., Burzynski, S.R.
Tissue culture and acute animal toxicity studies of antineoplaston A2
Future Trends in Chemotherapy 1985;6:481-484
1985
Burzynski, S.R., Hai TI.
Antineoplaston A10
Drugs of the Future 1985;10:103-105
1985
Burzynski, S.R.
Phase I clinical studies of antineoplaston AS2-5 injections
Recent Advances in Chemotherapy.
lshigami J. (Ed). University ofTokyo Press. 1985; Tokyo, Japan
1985
Burzynski, S.R.• Mohabbat. M.O., Burzynski, B.
Toxicology studies on oral formulation of antineoplaston A 10 in cancer patients
Future Trends in Chemotherapy 1985;6:485-493
1984
Burzynski, S.R., Mohabbat MO, Burzynski B.
Animal toxicology studies on oral formulation of antineoplaston A10
Drugs Exptl Clin Res 1984;10:113-118
1984
Lee, S.S., Mohabbat, M.O., Burzynski, S.R.
Tissue culture and animal toxicity studies of antineoplaston A2
Drugs Exptl Clin Res 1984;10:607-610
1984
Burzynski,S.R.
AntineoplastonA10.AnnualDrugDataReport 1984;6:124
1984
Burzynski, S.R., Mohabbat, M.O., Burzynski, B.
Human toxicology studies on oral formulation of antineoplaston A10
Drugs Exptl Clin Res 1984;10:891-909
1984
Burzynski,S.R.,Mohabbat,M.O.,Burzynski,B.
Toxicology studiesonoralformulationofantineoplastonA10in cancer patients
Drugs Exptl Clin Res 1984;10:611-619
1979
Beall, P., Szopa, B., Burzynski, S.R., Hazlewood, C.F.
Polypeptides that inhibit human breast cancer cell division
Cancer Biochem Biophy s 1979;3:93-96
1978
Burzynski, S.R.
Antyneoplastony
Przeglad Lekarski 1978;6:583-586
1977
Gross S, Galicka N. Grabarczyk M. Giannini M. Burzynski SR. Stolzmann Z.
Urinary peptides inhibit DNA
synthesis in vitro in certain cultured neoplastic cells
Clin Chern 1977;23:148-149
1977
Burzynski, S.R., Stolzmann. Z., Szopa, B., Stolzmann. E., Kaltenberg, O.P.
Antineoplaston A in cancer therapy
(1)
Physiol Chern Phys 1977;9:485-500
1976
Burzynski, S.R.
Antineoplastons: Biochemical defense against cancer
Physiol Chern Phys 1976;8:275-279
1976
Gross, S., Galicka, N., Burzynski, S.R., Stolzmann, A.
Urinary peptides in muscular dystrophy
Physiol Chern Phys 1976;8:161-166
1976
Burzynski, S.R
Sequential analysis in subnanomolar amounts of peptides; Determination of the structure of a habituation-induced brain peptide (ameletin)
Anal Biochem 1976;70:359-365
1976
Burzynski, S.R., Lao, T.L., Ho, D.H., Rao, P.N., Georgiades, J., Kratzenstein, H.
Biologically active peptides in human urine:
Ill. Inhibitors ofthe growth of leukemia, osteosarcoma and HeLa cells
Physiol Chern Phys 1976;8: 13-22
1976
Burzynski, S.R., Rao, P.N., Gross, S., Stolzman, Z.
lnhibition of the Growth ofHeLa Cells bythe Peptide Isolated from Normal Human Urine
Fed Proc 1976;35:623
1975
http://www.ncbi.nlm.nih.gov/m/pubmed/1130705
Burzynski. S.R.
Quantitative analysis of amino acids and peptides in the femtomolar range
Anal Biochem 1975;65:93-99
http://www.sciencedirect.com/science/article/pii/0003269775904959
Anal Biochem. 1975 May 12;65(1-2):93-99
Analytical Biochemistry
Volume 65, Issues 1–2, 12 May 1975, Pages 93–99
1975
Burzynski. S.R.. Ungar. G.
Brain Peptides Associated with Habituation to a Sound Stimulus
Neuroscience Abstracts 1975;1:329
1975
Ungar. G., Burzynski, S.R.• Tate. D.L.
Learning-induced Brain Peptides
Peptides:
Chemistry, structure and biology
Walter. R., Meienhofer. J. (Ed). Ann Arbor Science; 1975; Ann Arbor. Michigan. USA
1974
http://www.ncbi.nlm.nih.gov/m/pubmed/4548759
Burzynski, S.R., Ungar, A.L., Lubanski, E.
Biologically active peptides in human urine:
II. Effect on intestinal smooth muscle and heart
Physiol Chern Phys 1974;6:457-468
Physiol Chem Phys. 1974;6(5):457-68
1974
Burzynski, S.R., Ungar, A.L., Lubanski, E.
Effect of Urinary Peptides on Smooth Muscle and Heart
Fed Proc 1974;33:547
1973
http://www.ncbi.nlm.nih.gov/m/pubmed/4775589
Burzynski, S.R.
Biologically active peptides in human urine:
L Isolation of a group of medium-sized peptides
Physiol Chern Phys 1973;5:437-447
Physiol Chem Phys. 1973;5(5):437-47
1973
Burzynski, S.R., Georgiades, J.
Effect of Urinary Peptides on DNA, RNA and Protein Synthesis in Normal and Neoplastic Cells
Fed Proc 1973;32:766
1973
Ungar, G., Burzynski, S.R
Isolation and Purification of a Habituation-inducing Peptide from Trained Rat Brain
Fed Proc 1973;32:367
1970
Burzynski , S., Czerniak, Z.
A simple method for the separation of free and bound amino acids and its application to the identification of bound amino acids in human blood serum
Chern Anal 1970;15:223-225
1970
http://www.ncbi.nlm.nih.gov/m/pubmed/5531748
Szajner-Milart, J., Burzynski. S.R . Paczos-Chadyma. E.. Czerniak, Z.
Free amino acids in serum of obese children
Endokr Pol 1970;21:611-617
Endokrynol Pol. 1970;21(6):611-7. Article in Polish
1969
Krzeczkowska, 1., Czerniak, Z.. Burzynski. S.
Quantitative determinations of carbohydrates and their statistical analysis
L Results obtained in various conditions using paper and thin-layer chromatography
Chern Anal
1969 ; 1 3 : 1221 – 1228
1969
Burzynski. S.
Investigations on unknown ninhydrin-reacting substances in human blood serum L Attempts at identification ofthree such substances
Experientia 1969;25:490-491
1969
http://www.ncbi.nlm.nih.gov/m/pubmed/5801388
Burzynski. S.
Bound amino acids in serum of patients with chronic renal insufficiency
Clin Chim Acta 1969;25:231 -237
http://www.sciencedirect.com/science/article/pii/0009898169902599
Clin Chim Acta. 1969 Aug;25(2):231-7
Clinica Chimica Acta
Volume 25, Issue 2, August 1969, Pages 231–237
1969
http://www.ncbi.nlm.nih.gov/m/pubmed/5797414
Czerniak, Z., Burzynski, S.
Free amino acids in serum of patients with chronic renal insufficiency
Clin Chim Acta 1969;24:367-372
http://www.sciencedirect.com/science/article/pii/0009898169901077
Clin Chim Acta. 1969 Jun;24(3):367-72
Clinica Chimica Acta
Volume 24, Issue 3, June 1969, Pages 367–372
1969
Burzynski, S., Czerniak, Z.
A simple method for free and bound amino acid separation
Folia Soc Sci Lub 1969/70;Sec. A-D 9/10 (suppl):143-144
1969
http://www.ncbi.nlm.nih.gov/m/pubmed/5996246
Burzynski, S., Czerniak, Z.
Quantitative determination of amino acids using photometry of negative printed chromatograms
Modification of the method and its application for amino acid analysis in blood serum
Chern Anal 1969;14:667-671
Ann Univ Mariae Curie Sklodowska Med. 1966;21:125-34. Article in Polish
1969
Czerniak, Z., Burzynski, S.
Qualitative analysis of amino acids using the multiple development of chromatograms in different eluents
Chem Anal 1969;14:673-676
1968
Krzeczkowska, L, Czerniak, Z., Burzynski, S.
Quantitative determinations of free amino acids in human blood with the use of our own method and Beckman amino acid analyzer
Pol Arch Med W ewn 1968;40:223-228
1968
Krzeczkowska, L, Czerniak, Z., Burzynski, S.
Quantitative determinations of free amino acids in the blood of patients with myocardial infarction using a new method of photometry of the negative printed chromatograms
Pol Arch Med Wewn 1968;41:361-368
1968
Krzeczkowska, L, Czerniak, Z.. Burzynski, S.
Quantitative determinations of carbohydrates and their statistical analysis, IL Analysis of variance for four-crossed classification and Tukey confidence intervals
Chern Anal 1968; 13: 1229-1238
1968
Burzynski. S.
Investigations on amino acids and peptides in blood serum of healthy people and patients with chronic renal insufficiency
1968; Lublin. Poland: 274 pp (doctoral dissertation)
1966
http://www.ncbi.nlm.nih.gov/m/pubmed/5996246
Krzeczkowska. 1., Burzynski, S. Czerniak Z.
Quantitative determination of amino acids using photometry of negative printed chromatograms
Ann Univ MC Sklodowska 1966;21:125-134
Ann Univ Mariae Curie Sklodowska Med. 1966;21:125-34. Article in Polish
1966
Krzeczkowska. 1., Czerniak. Z., Burzynski, S.
The application ofthe negative printed chromatograms for quantitative determination of free amino acids in the blood of healthy people
Ann Univ MC Sklodowska 1966; 2 1: 313-322
1965
Krzeczkowska, 1., Burzynski, S., Czerniak. Z.
Investigations on the possibility ofthe determination of mushroom species on the basis ofthe composition of their amino acids
Ann Univ MC Sklodowska 1965;20:221-229
1965
Krzeczkowska, L, Czerniak, Z., Burzynski, S.
Free and bound amino acids of some edible mushrooms
Ann Univ MC Sklodowska 1965;20:303-312
1964
http://www.ncbi.nlm.nih.gov/m/pubmed/5893108
Krzeczkowska, L, Czerniak, Z., Burzynski, S.
Bound amino acids of some edible mushrooms
Ann Univ MC Sklodowska 1964;19:329-336
Ann Univ Mariae Curie Sklodowska Med. 1964;19:329-36. Article in Polish
1964
http://www.ncbi.nlm.nih.gov/m/pubmed/5893107
Krzeczkowska, L, Burzynski, S., Czerniak, Z.
Free amino acids of some edible mushrooms
Ann Univ MC Sklodowska 1964;19:321-328
Ann Univ Mariae Curie Sklodowska Med. 1964;19:321-8. Article in Polish
SELECTED ABSTRACTS OF PRESENTATIONS BY S.R. BURZYNSKI AND ASSOCIATES
11/16 – 22/2010
Burzynski, S.R, Weaver, RA, Janicki, T.J., Burzynski, G.S., Szymkowski, B., Acelar, S.S.
OT-15
Preliminary results of a phase II study of antineoplastons A 10 and AS2-1 (ANP) in adult patients with recurrent mixed gliomas
Presented at the 15th Annual Scientific Meeting ofthe Society for Neuro-Oncology; November 16-22, 2010; Montreal, Quebec, Canada
11/16 – 22/2010
Patil, S., Burzynski, S.R, Mrowczynski, E., Grela, K.
CB-15
Targeting microRNAs in glioma cells with antineoplastons
Presented at the 15th Annual Scientific Meeting ofthe Society for Neuro-Oncology; November 16-22, 2010; Montreal, Quebec, Canada
6/20- 23/2010
Burzynski, S.R, Weaver, RA. Janicki, T.. E. Szymkowski, B.•Acelar. S.S., Burzynski, G.S.
A phase II study of antineoplaston A 10 and AS2-1 injections in children with low-9rade astrocytomas
Presented at the 14th International Symposium on Pediatric Neuro-Oncology (ISPNO); June 20-23, 2010; Vienna. Austria
6/20 – 23/2010
Patil, S., Burzynski, S.R. Mrowczynski, E.• Grela, K.
Antineoplastons initiate caspase induced apoptosis by suppressing survivin expression in U87 glioblastoma cells
Presented at the 14th International Symposium on Pediatric Neuro-Oncology (ISPNO); June 20-23, 2010; Vienna. Austria
5/11 – 14/2009
Burzynski, S.R.•Janicki, T.J.•Weaver. RA. Szymkowski, B.• Burzynski, G.S.
Phase II study of antineoplastons A 10 and AS2-1 in patients with brainstem glioma
Protocol BC-BT-11
Presented at the 3rd Quadrennial Meeting oftheWorld Federation ofNeuro-Oncology jointly with the 6th Meeting ofthe Asian Society for Neuro-Oncology; May 11-14. 2009; Yokohama. Japan
5/11 – 14/2009
Weaver. RA. Szymkowski, B.• Burzynski, S.R.
Over a 10-year survival andcomplete response ofa patientwith diffuse intrinsic brainstem glioma (DBSG) treated with antineoplastons (ANP)
Presented at the 3rd Quadrennial Meeting ofthe World Federation ofNeuro-Oncology jointly with the 6th Meeting ofthe Asian Society for Neuro- Oncology; May 11-14. 2009; Yokohama. Japan
5/11 – 14/2009
Patil, S., Burzynski, S.R., Chittur, S., Mrowczynski, E., Grela, K.
Antineoplastons inhibit MCM complex in glioblastoma cells
Presented at the 3rd Quadrennial Meeting ofthe World Federation ofNeuro-Oncology jointly with the 6th Meeting ofthe Asian Society for Neuro-Oncology; May 11-14. 2009; Yokohama. Japan
4/21 – 25/2009
Burzynski, S.R.
New research on molecular mechanisms and prevention of Alzheimer's disease
Presented at the 17th Annual world Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies, Spring 2009 Session; Aprii 21-April 25, 2009; Orlando, Florida
3/19 – 21/2009
Burzynski, S.
Life extension through application ofchromatin remodeling agents
Presented at the 7th Anti- Aging Medicine World Congress & Medispa; March 19-March 21, 2009; Monte-Carlo, Monaco
Marquis, A , Kubove, E., W alczak, M., Burzynski, S.
Hepatocellular carcinoma, recurrent after standard therapy, ~llrrP~~flllht trP::~fPrt with :~ rnmhin::~tinn nft::~rnPIPrt thPr::~niP~ PrP~PntPrt ::~t thP ?nth lntPrn::~tinn::~l r.nnnrP~~ nn
SELECTED ABSTRACTS OF PRESENTATIONS BY S.R. BURZYNSKI AND ASSOCIATES
Burzynski, S.R, Weaver, RA, Janicki, T.J., Burzynski, G.S., Szymkowski, B., Acelar, S.S.
OT-15
Preliminary results of a phase II study of antineoplastons A 10 and AS2-1 (ANP) in adult patients with recurrent mixed gliomas
Presented at the 15th Annual Scientific Meeting ofthe Society for Neuro-Oncology; November 16-22, 2010; Montreal, Quebec, Canada
Patil, S., Burzynski, S.R, Mrowczynski, E., Grela, K.
CB-15
Targeting microRNAs in glioma cells with antineoplastons
Presented at the 15th Annual Scientific Meeting ofthe Society for Neuro-Oncology; November 16-22, 2010; Montreal, Quebec, Canada
Burzynski, S.R, Weaver, RA. Janicki, T.. E. Szymkowski, B.•Acelar. S.S., Burzynski, G.S.
A phase II study of antineoplaston A 10 and AS2-1 injections in children with low-9rade astrocytomas
Presented at the 14th International Symposium on Pediatric Neuro-Oncology (ISPNO); June 20-23, 2010; Vienna. Austria
Patil, S., Burzynski, S.R. Mrowczynski, E.• Grela, K.
Antineoplastons initiate caspase induced apoptosis by suppressing survivin expression in U87 glioblastoma cells
Presented at the 14th International Symposium on Pediatric Neuro-Oncology (ISPNO); June 20-23, 2010; Vienna. Austria
Burzynski, S.R.•Janicki, T.J.•Weaver. RA. Szymkowski, B.• Burzynski, G.S.
Phase II study of antineoplastons A 10 and AS2-1 in patients with brainstem glioma
Protocol BC-BT-11
Presented at the 3rd Quadrennial Meeting oftheWorld Federation ofNeuro-Oncology jointly with the 6th Meeting ofthe Asian Society for Neuro-Oncology; May 11-14. 2009; Yokohama. Japan
Weaver. RA. Szymkowski, B.• Burzynski, S.R.
Over a 10-year survival andcomplete response ofa patientwith diffuse intrinsic brainstem glioma (DBSG) treated with antineoplastons (ANP)
Presented at the 3rd Quadrennial Meeting ofthe World Federation ofNeuro-Oncology jointly with the 6th Meeting ofthe Asian Society for Neuro- Oncology; May 11-14. 2009; Yokohama. Japan
Patil, S., Burzynski, S.R., Chittur, S., Mrowczynski, E., Grela, K.
Antineoplastons inhibit MCM complex in glioblastoma cells
Presented at the 3rd Quadrennial Meeting ofthe World Federation ofNeuro-Oncology jointly with the 6th Meeting ofthe Asian Society for Neuro-Oncology; May 11-14. 2009; Yokohama. Japan
Burzynski, S.R.
New research on molecular mechanisms and prevention of Alzheimer's disease
Presented at the 17th Annual world Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies, Spring 2009 Session; Aprii 2 1-April 25, 2009; Orlando, Florida
Burzynski, S.
Life extension through application ofchromatin remodeling agents
Presented at the 7th Anti- Aging Medicine World Congress & Medispa; March 19-March 21, 2009; Monte-Carlo, Monaco
Marquis, A , Kubove, E., W alczak, M., Burzynski, S.
Hepatocellular carcinoma, recurrent after standard therapy, ~llrrP~~flllht trP::~fPrt with :~ rnmhin::~tinn nft::~rnPIPrt thPr::~niP~ PrP~PntPrt ::~t thP ?nth lntPrn::~tinn::~l r.nnnrP~~ nn
Anti-Cancer Treatment; February 3-February 6, 2009; Paris, France
W eaver, R, De Leon, L, Burzynski, S_
A complete response in a patient with inoperable adenocarcinoma ofthe head of the pancreas treated with a combination of gene-targeted therapies
Presented at the 20th International Congress on Anti-Cancer Treatment; February 3-February 6, 2009; Paris, France
Burzynski, S.R.
The Coming Pandemic of Liver Cancer
In Search of Genomic Solutions. Presented at the 16th Annual World Congress of A 4 M, Winter 2008 Session; December 12 – December 15, 2008; Las Vegas, Nevada
Burzynski, S.R., Weaver, R., Janicki, T., Szymkowski, B., Samuel, S., Burzynski, G.
Phase II study of antineoplastons A 10 and AS2-1 (ANP) in patients with newly diagnosed anaplastic astrocytoma:
A preliminary report
Presented at the 13th Annual Scientific Meeting ofthe Society for Neuro-Oncology; November 20- November 23, 2008; Las Vegas, Nevada
Burzynski, S.R., Patil, S., Chittur, S., Mrowczynski, E., Grela, K.
Antineoplaston AS2-1 affects cell cycle checkpoints leading to apoptosis in human glioblastoma cells
Presented at the 13th Annual Scientific Meeting of the Society for Neuro-Oncology; November 20-November 23, 2008; Las Vegas, Nevada
Burzynski, S.R., Patil, S., llkowska-Musial, E., Chittur, S., Gupta, V., Sarangi, R.
Pathway analysis ofthe effect of chromatin remodeling agent phenylbutyrate on the brains of honeybees
Presented at Neuroscience 2008; November 15-November 19, 2008; Washington D.C.
Burzynski, S.R.
Practical Application of Gene Silencing Theory ofAging
Life Extension in Animals and Human Clinical Trials
Presented at the Dubai Congress on Anti-Aging and Aesthetic Medicine (DCAAAM); November 7- November 9, 2008; Dubai
Burzynski, S.R.
Antineoplastons and Targeted Gene Therapy
Presented at ACAM Scientific Conference; October 15-0ctober 19, 2008; Las Vegas, Nevada
Burzynski, S.R., Weaver, R., Janicki, T., Szymkowski, B., Walczak, M., Burzynski, G.
Phase II study of antineoplastons A 10 and AS2-1 infusions (ANP) in patients with recurrent anaplastic astrocytoma
Presented at the European Association for NeuroOncology (EANO); September 12-September 14, 2008; Barcelona, Spain
Patil, S., Burzynski, S.R., Chittur, E., Mrowczynski, K.G.
The ingredients of antineoplaston AS2-1 down- regulate glycolysis pathways in glioblastoma cells
Presented at the European Association for NeuroOncology (EANO); September 12-September 14, 2008; Barcelona, Spain
Burzynski, S.R.
Practical application ofgene silencing theory of aging
Life extension in animal testing and human clinical trials
Presented at the European Congress on Anti-Aging & Aesthetic Medicine (ECAAAM); September 11-September 14, 2008; Dusseldorf, Germany
Burzynski, S.R., Weaver, R., Janicki, T., Walczak, M., Szymkowski, B., Samuel, S.
Phase II study of antineoplastons A 10 and AS2-1 (ANP) in children with optic pathway glioma:
A preliminary report
Presented at the 13th International Symposium on Pediatric Neuro-Oncology; June 29.July 2, 2008; Chicago, Illinois
Burzynski, S.R.
Genome, Epigenome and Aging
Presented at the First Annual Iberian Congress on Anti-Aging Medicine and Biomedical Technologies; May 29-31, 2008; Estoril, Portugal
Burzynski, S.R_
Personalized Cancer Treatment in Genomics Era_
Presented at the First Annual Iberian Congress on Anti-Aging Medicine and Biomedical Technologies; May 29-31, 2008; Estoril, Portugal
Burzynski, S.R.
Practical application of gene silencing theory of aging
Life extension in animals and human clinical trials
Presented at the 16th Annual W orld Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies; April 25-27, 2008; Orlando, Florida
Burzynski, S.R.
Antineoplaston peptides in treating cancer
Presented at the 2008 Orthomolecular Health- Medicine conference; February 29-March 2, 2008; San Francisco, California
Burzynski, S.R.
Anti-Aging peptides- a new frontier in healing
Presented at the 2008 Orthomolecular Health- Medicine conference; February 29-March 2, 2008; San Francisco, California
Burzynski, S.R.
Genomic approach to cancer treatment
Presented at the 15th Annual World Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies; December 12-15, 2007; Las Vegas, Nevada
Burzynski,S.R.
GenomicsinCancerTreatment
Presentedatthe1stAnnualIndiaConferenceonAnti-Aging and Regenerative Medicine; November 16-18, 2007; Mumbai, India
Burzynski, S.R.
Epigenomic Approach to Anti-Aging
Presented at the 1st Annual India Conference on Anti- Aging and Regenerative Medicine; November 16-18, 2007; Mumbai, India
Burzynski, S.R., Weaver, RA , Szymkowski, B.
A case report ofa complete response and20-year suO/ivai of a patient with a recurrent, diffuse. intrinsic brainstem anaplastic astrocytoma_
Presented at the Society for Neuro- Oncology 12th Annual Scientific Meeting; November 15-18, 2007; Dallas, Texas
Patil, S., Burzynski, S.R., Mrowczynski, E., Grela, K.
Phenylacetylglutamine (PG) and phenylacetate (PN) interact additively to produce detachment-induced apoptosis/anoikis in glioblastoma cells
Presented at the Society for Neuro-Oncology 12th Annual Scientific Meeting; November 15-18, 2007; Dallas, Texas
Burzynski, S.R., Tempczyk-Russell, A., llkowska-Musial, E.
Amyloid precursor protein (APP) and related protein fragmentation in consolidation of memory
Presented at Neuroscience 2007, the Society's Annual Meeting; November 3-7, 2007; Sand Diego, California
Burzynski, S.R.
Epigenomic approach to anti-aging
Presented at:
4th Congresso lnternacional de Antienvelhecimento; October 26-27, 2007; Sao Paulo, Brazil
Burzynski, S.R.
Nutrition and ageing :
Gene silencing or gene activation
Presented at: 10th European Nutrition Conference; July 10-13, 2007; Paris, France
Burzynski, S.R.
La solution genetique contre le vieillissement Presented at:
Anti-Aging Medicine World Congress; March 22-24, 2007; Monte Carlo
Burzynski, S.R.
Genetics of Brain Aging (II)
Genetic Mechanisms in Encoding and Consolidation of Memory
Presented at:
14th Annual International Congress on Anti-Aging Medicine; December 7-10, 2006; Las Vegas, Nevada
Burzynski, S.R., Janicki, T.J., Weaver, RA , Szymkowski, B.J., Khan, M.l., Dolgopolov, V.
Treatment of multicentric brainstem ~liomas with Antineoplastons (ANP) A 10 and AS2-1
Presented at the Society for Neuro-
Didymus Judas Thomas' Hipocritical Oath Blog 